flow trial semaglutide kidney outcomes In FLOW, semaglutide, a GLP-1 RA, reduced the risk of major outcomes, MACE and all-cause mortality in people with T2D and CKD, regardless of baseline mineralocorticoid receptor antagonist use. @ADA_Pubs Read Semaglutides Are Poised to Remake

Feeding ALCAR can also benefit performance horses affected by muscle soreness and stiffness

Want to understand the genetic pathways behind your own biology

Both increase dehydration risk, so adequate water intake becomes especially important during combination therapy

These dulaglutide-mediated reductions in alcohol drinking and preference for alcohol were also evident in female rats (Vallof et al., 2020), an outcome that was not seen previously

What Healthcare Leaders Need to Know Now Current Regulatory Reality The 14 peptides discussed publicly remain Category 2 substances

Benefits of L-Arginine: Knowing the Good Guys from the Bad Research has shown that in intravenous or supplement form, L-arginine supports the production of one of the good guysendothelium-derived nitric oxide (EDNO)